Evaluation of natural and nitramine binding energies to 3-D models of the S1S2 domains in the N-methyl-D-aspartate receptor

被引:0
|
作者
Jason Ford-Green
Olexandr Isayev
Leonid Gorb
Edward J. Perkins
Jerzy Leszczynski
机构
[1] Jackson State University,Interdisciplinary Center for Nanotoxicity
[2] Environmental Laboratory,Department of Chemistry
[3] US Army ERDC,undefined
[4] Case Western Reserve University,undefined
[5] Badger Technical Services,undefined
来源
Journal of Molecular Modeling | 2012年 / 18卷
关键词
Homology modeling; Molecular dynamics; Molecular docking; NMDAR; RDX; HMX;
D O I
暂无
中图分类号
学科分类号
摘要
Overactivation of the N-methyl-D-aspartate receptor (NMDAR) in postsynaptic neurons leads to glutamate-related excitotoxicity in the central nervous system of mammals. We have built 3-D models of each domain for the universal screening of potential toxicants and their binding mechanisms. Our docking results show that the calculated pKi values of glycine and L-glutamate significantly increase (>1) when the NR1 and NR2A S1S2 domains are closing, respectively. Inversely, D-cycloserine (DCS) and 5,7-dichlorokynurenic acid (5,7-DCKA) do not show such a dependence on domain closure. Replica exchange molecular dynamics (REMD) confirmed 5 different conformational states of the S1S2 domain along the 308.2 K temperature trajectory. Analysis of residue fluctuations during this temperature trajectory showed that residues in loop 1, loop 2, the amino terminal domain (ATD), and the area linked to ion channel α-helices are involved in this movement. This further implicates the notion that efficacious ligands act through S1S2 lobe movement which can culminate in the opening or closing of the ion channel. We further tested this by docking hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) and octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocane (HMX) to the S1S2 domain. Our results predict that these nitramines are not efficacious and thus do not produce excitoxicity when they bind to the S1S2 domain of the NMDAR.
引用
收藏
页码:1273 / 1284
页数:11
相关论文
共 50 条
  • [41] SPERMINE ENHANCES BINDING TO THE GLYCINE SITE ASSOCIATED WITH THE N-METHYL-D-ASPARTATE RECEPTOR COMPLEX
    SACAAN, AI
    JOHNSON, KM
    MOLECULAR PHARMACOLOGY, 1989, 36 (06) : 836 - 839
  • [42] Influence of subchronic manganese sulfate on binding of a competitive N-methyl-D-aspartate receptor antagonist
    Wu, Q
    Komiskey, HL
    Mbawuike, P
    Childress, V
    FASEB JOURNAL, 2002, 16 (05): : A951 - A951
  • [43] MOLECULAR DESIGN OF THE N-METHYL-D-ASPARTATE RECEPTOR-BINDING SITE FOR PHENCYCLIDINE AND DIZOLCIPINE
    FERRERMONTIEL, AV
    SUN, W
    MONTAL, M
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) : 8021 - 8025
  • [44] Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-D-aspartate receptor complex
    Bence, AK
    Rogers, DT
    Worthen, DR
    Fu, M
    Littleton, JM
    Crooks, PA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (23) : 2621 - 2623
  • [45] PRESERVATION OF POLYAMINE AND REDOX MODULATORY DOMAINS OF THE N-METHYL-D-ASPARTATE RECEPTOR IN ALZHEIMERS-DISEASE
    PALMER, AM
    BURNS, MA
    JOURNAL OF NEUROCHEMISTRY, 1993, 61 : S175 - S175
  • [46] Expression of N-methyl-D-aspartate receptor 1 in rats with chronic ocular hypertension
    Kim, J. H.
    Lee, N. Y.
    Jung, S. W.
    Park, C. K.
    NEUROSCIENCE, 2007, 149 (04) : 908 - 916
  • [47] Translational regulation of the N-methyl-D-aspartate receptor subunit NR1
    Vazhappilly, R
    Sucher, NJ
    NEUROSIGNALS, 2004, 13 (04) : 190 - 193
  • [48] Structural Mechanism of N-Methyl-D-Aspartate Receptor Type 1 Partial Agonism
    Ylilauri, Mikko
    Pentikainen, Olli T.
    PLOS ONE, 2012, 7 (10):
  • [49] D1 D2 DOPAMINE AND N-METHYL-D-ASPARTATE (NMDA) RECEPTOR PARTICIPATION IN EXPERIMENTAL CATALEPSY IN RATS
    VERMA, A
    KULKARNI, SK
    PSYCHOPHARMACOLOGY, 1992, 109 (04) : 477 - 483
  • [50] Sensitivity of the N-methyl-D-aspartate receptor channel to butyrophenones is dependent on the ε2 subunit
    Yamakura, T
    Sakimura, K
    Mishina, M
    Shimoji, K
    NEUROPHARMACOLOGY, 1998, 37 (06) : 709 - 717